2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1515

Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials
Abstract Number: 40

Inflammation and Neuronal Growth Factors in Rheumatoid Arthritis
Abstract Number: 477

Inflammation but Also Pain and Function, and Psychological Impact Is Related to Non-Acceptable Status in Patients with Rheumatoid Arthritis: A Factorial Analysis in 643 Patients
Abstract Number: 1806

Inflammatory Arthritis Induced by Immune Checkpoint Inhibitor Therapy: A Distinct Clinical Entity and Immunologic Phenotype
Abstract Number: 1522

Inflammatory Bowel Disease and Anterior Uveitis in Patients Treated with Ixekizumab for Radiographic Axial Spondyloarthritis: Results from Two Phase 3 Studies Through 52 Weeks
Abstract Number: 1910

Inflammatory Processes in Experimental Spondyloarthritis Are Accompanied by Formation of Ectopic Lymphoid Structures and B Cell Lineage Alterations in the Bone Marrow
Abstract Number: 1486

Infliximab Serum Trough Levels Predict Non-clinical Response in Patients with Axial Spondyloarthritis
Abstract Number: 1169

Influence of Steroid Treatment on 18F-FDG PET/CT Accuracy to Detect Vascular and Musculoeskeletal Involvement in Patients with Polymyalgia Reumatica
Abstract Number: 2363

Influence of the Clinical Characteristics and Different Genetic Polymorphisms Related to MTX, on the Efficacy and Safety in Patients with RA Treated with MTX in Monotherapy
Abstract Number: 2537

Influential Factors in Promoting Treat-to-Target for Systemic Lupus Erythematosus via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)
Abstract Number: 1200

Influenza Vaccination Rates Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Immunosuppressive Therapy: Findings from a Large Public Hospital
Abstract Number: 306

Infrequent Screening but High Prevalence of Antinuclear Antibodies in Patients with Neuropsychiatric Disorders
Abstract Number: 2028

Inhibited Expression of Hematopoietic Progenitor Kinase 1 in Tfh Cells Contributes to Autoimmunity in Systemic Lupus Erythematosus
Abstract Number: 985

Inhibition of Calcium/calmodulin-dependent Protein Kinase IV in Rheumatoid Arthritis: Dual Effect on Th17 Cell Activation and Osteoclastogenesis
Abstract Number: 1991

Inhibition of CD44 Intracellular Domain Production Suppresses Bovine Articular Chondrocyte De-differentiation Induced by Excessive Mechanical Stress Loading

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].